Mereo BioPharma (MREO) Cash & Equivalents (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Cash & Equivalents data on file, last reported at $36.2 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $36.2 million, down 42.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.2 million (down 42.04% YoY), and the FY2025 annual result was $41.0 million, down 41.27% from the prior year.
• Cash & Equivalents declined to $36.2 million in Q1 2026 per MREO's latest filing, from $41.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $87.4 million in Q2 2024 and troughed at $36.2 million in Q1 2026.
• A 5-year average of $59.5 million and a median of $57.4 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents sank 48.02% in 2022, then gained 28.44% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $66.1 million in 2022, then decreased by 13.1% to $57.4 million in 2023, then rose by 21.56% to $69.8 million in 2024, then plunged by 41.27% to $41.0 million in 2025, then declined by 11.63% to $36.2 million in 2026.
• Business Quant data shows MREO's Cash & Equivalents at $36.2 million in Q1 2026, $41.0 million in Q4 2025, and $48.7 million in Q3 2025.